Dupilumab for Erythrodermic AD: Results From a Pooled Subgroup Analysis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Dupilumab monotherapy or with concurrent TCS shown to significantly improve signs, symptoms, and quality of life in patients with erythrodermic AD in multiple randomized, placebo-controlled, double-blinded trials.
Format: Microsoft PowerPoint (.ppt)
File Size: 171 KB
Released: July 27, 2020

Acknowledgements

Provided by Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer, Inc.

Related Content

Expert faculty Benjamin Ungar, MD, discusses current and future treatment options for patients with prurigo nodularis (PN) from Clinical Care Options (CCO).

Benjamin Ungar, MD Released: September 16, 2022

Expert commentary reviews key concepts in the diagnosis and treatment of chronic spontaneous urticaria from Clinical Care Options (CCO).

Jonathan A. Bernstein, MD Released: September 15, 2022

Expert slides on new and emerging therapies, reducing healthcare disparities, and transitions of care in the management of moderate to severe atopic dermatitis

Robert Sidbury, MD, MPH Benjamin Ungar, MD Released: September 9, 2022

From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.

Robert Sidbury, MD, MPH Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings